About Regenus

Regeneus is an Australian biotechnology company aiming to improve the quality of life of patients suffering from pain.

We develop regenerative medicine products that interrupt the inflammatory cascade that leads to pain in the first place. Worldwide, there are hundreds of millions of patients suffering from short-term and chronic pain. Regeneus listed on the Australian Securities Exchange (ASX) in June 2013 under the ticker code ‘RGS’.

Investment highlight

Regeneus is focused on the US$69 billion global pain market, starting with commercialising Progenza for osteoarthritis in Japan

Latest news & insights

See below for the latest updates on the Company's activity.

Regeneus receives milestone payment from Kyocera

Australian biotechnology and life sciences online news source, BiotechDaily, reported that Regeneus received a non-refundable milestone payment of approximately $1.6 million (100 million Japanese Yen) from Kyocera Corporation as set out in the non-binding Memorandum of Understanding (MOU) signed on 2 March 2020.

Read the full article here.

Regeneus inks agreement with high profile Japanese life sciences group

Online investment publication Finfeed reported that Regeneus signed a non-binding memorandum of understanding (MOU) with Kyocera Corporation (Kyocera, TYO:6971), a diversified Japanese-based manufacturer with a strong position in the life sciences industry.

Read the full article here.

Regeneus (ASX:RGS) signs MOU with Kyocera for Progenza

The Market Herald - a leading source of authoritative breaking stock market news for self-directed investors - published an article reporting on Regeneus signing a non-binding memorandum of understanding with Kyocera Corporation.

Read the full article here.

See more

Enquiries

If you have any enquiries please contact us

Contact us